瑞替普酶联合低分子肝素钙治疗急性心肌梗死的疗效观察  

Observation on Efficacy of Reteplase Combined with Low Molecular Weight Heparin Calcium in Treatment of Acute Myocardial Infarction

作　　者：戴萍[1] 范正宏[2] 

机构地区：[1]武汉市第一医院药剂科,湖北武汉430022 [2]武汉市第一医院心内科,湖北武汉430022

出　　处：《中国医院用药评价与分析》2018年第1期43-45,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨瑞替普酶联合低分子肝素钙治疗急性心肌梗死的临床疗效。方法:选取2014年6月—2016年6月武汉市第一医院收治的急性心肌梗死患者104例作为研究对象,以随机数字表法分为观察组和对照组,每组52例。对照组患者给予注射用瑞替普酶联合肝素钠注射液,观察组患者给予注射用瑞替普酶联合低分子肝素钙注射液。观察两组患者的临床疗效、各项临床指标和并发症发生情况。结果:观察组、对照组患者的总有效率分别为92.31%(48/52)、88.46%(46/52),差异无统计学意义(P>0.05);观察组患者胸痛缓解时间和静息心电图ST段回降>50%时间明显短于对照组,差异均有统计学意义(P<0.05);两组患者12 h内血管再通率的差异无统计学意义(P>0.05);观察组患者并发症发生率为9.62%(5/52),明显低于对照组的25.00%(13/52),差异有统计学意义(P<0.05)。结论:瑞替普酶联合低分子肝素钙治疗急性心肌梗死的疗效显著,可改善患者症状,且并发症少,安全性高。OBJECTIVE： To probe into the clinical efficacy of reteplase combined with low molecular weight heparin calcium in treatment of acute myocardial infarction. METHODS： 104 patients with acute myocardial infarction admitted into Wuhan No. 1 Hospital from Jun. 2014 to Jun. 2016 were selected and divided into observation group and control group via random number table,with 52 cases in each. The control group was given reteplase injection combined with heparin sodium injection,while the observation group was given reteplase combined with low molecular weight heparin calcium for injection. Clinical efficacy,clinical indices and incidences of complications of two groups were observed. RESULTS： The total effective rates of observation group and control group were respectively 92. 31%（ 48/52） and 88. 46%（ 46/52）,the difference had no statistical significance（ P〈0. 05）; the relief time of chest pain and 50% fall back time of ST segment of observation group were significantly shorter than those of the control group,with statistically significant differences（ P〈0. 05）; there was no statistical significance in the difference of the recanalization rate of vessel with 12 h between two groups（ P〈0. 05）; the incidence of complications of observation group（ 9. 62%,5/52） was significantly lower than that of the control group（ 25. 00%,13/52）,with statistically significant difference（ P〈0. 05）. CONCLUSIONS： The efficacy of reteplase combined with low molecular weight heparin calcium in treatment of acute myocardial infarction is remarkable,which can significantly improve patients＇ symptoms,with few complications and high safety.

关 键 词：瑞替普酶 低分子肝素钙 急性心肌梗死 

分 类 号：R972[医药卫生—药品]